BIOVENTIX PLC

Legal Proceedings Report • Aug 21, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Bioventix Announces License Agreement

PR Newswire

London, August 20

                             Bioventix plc                        ("Bioventix" or the "Company")                     Bioventix Announces License AgreementThe Company has signed a license agreement with DIAsource ImmunoAssays S.A. ofBelgium ("DIAsource") in relation to certain intellectual property owned byDIAsource.In April 2014, the Company announced that it was taking action to opposeDIAsource's European patent in the field of anti-vitamin D antibodies and theiruse in assays (i.e. tests) for vitamin D sufficiency and deficiency.  Thispatent is within the scope of the license which DIAsource has granted to theCompany and hence it will cease potentially to restrict Bioventix's business.The license features reasonable commercial terms and Bioventix will withdrawthe opposition to the European patent.Peter Harrison, CEO of Bioventix plc said "We considered the costs of apotential dispute together with the impact of on-going uncertainty on customersand shareholders and concluded that a license agreement with DIAsource was thepreferred outcome. With the license agreement now signed, Bioventix's businessis no longer potentially restricted by DIAsource's European patent."For further information please contact:Bioventix plc              Chief Executive Officer     Tel: 01252 728 001Peter HarrisonfinnCap Ltd                Corporate Finance           Tel: 020 7220 0500Geoff Nash/Simon Hicks     Corporate BrokingSteve NorcrossAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.